Characterization and Carbohydrate Specificity of Pradimicin S

Overview

Journal J Am Chem Soc

Publisher American Chemical Society

Specialty Chemistry

Date 2012 Jul 14

PMID 22788706

Citations 6

Authors

Syed Shahzad-Ul-Hussan

Rodolfo Ghirlando

Cajetan I Dogo-Isonagie

Yasuhiro Igarashi

Jan Balzarini

Carole A Bewley

Affiliations

Soon will be listed here.

Abstract

The pradimicin family of antibiotics is attracting attention due to its anti-infective properties and as a model for understanding the requirements for carbohydrate recognition by small molecules. Members of the pradimicin family are unique among natural products in their ability to bind sugars in a Ca(2+)-dependent manner, but the oligomerization to insoluble aggregates that occurs upon Ca(2+) binding has prevented detailed characterization of their carbohydrate specificity and biologically relevant form. Here we take advantage of the water solubility of pradimicin S (PRM-S), a sulfated glucose-containing analogue of pradimicin A (PRM-A), to show by NMR spectroscopy and analytical ultracentrifugation that at biologically relevant concentrations, PRM-S binds Ca(2+) to form a tetrameric species that selectively binds and engulfs the trisaccharide Manα1-3(Manα1-6)Man over mannose or mannobiose. In functional HIV-1 entry assays, IC(50) values of 2-4 μM for PRM-S corrrelate with the concentrations at which oligomerization occurs as well as the affinities with which PRM-S binds the HIV surface envelope glycoprotein gp120. Together these data reveal the biologically active form of PRM-S, provide an explanation for previous speculations that PRM-A may contain a second mannose binding site, and expand our understanding of the characteristics that can engender a small molecule with the ability to function as a carbohydrate receptor.

Citing Articles

Chemistry and biology of specialized metabolites produced by .

Dashti Y, Errington J Nat Prod Rep. 2023; 41(3):370-401.

PMID: 38099919 PMC: 10951976. DOI: 10.1039/d3np00047h.

Mannose-binding analysis and biological application of pradimicins.

Nakagawa Y, Ito Y Proc Jpn Acad Ser B Phys Biol Sci. 2022; 98(1):15-29.

PMID: 35013028 PMC: 8795531. DOI: 10.2183/pjab.98.002.

An Engineered Microvirin Variant with Identical Structural Domains Potently Inhibits Human Immunodeficiency Virus and Hepatitis C Virus Cellular Entry.

Shahid M, Qadir A, Yang J, Ahmad I, Zahid H, Mirza S Viruses. 2020; 12(2).

PMID: 32054060 PMC: 7077325. DOI: 10.3390/v12020199.

Carbohydrate Recognition Specificity of Trans-sialidase Lectin Domain from Trypanosoma congolense.

Waespy M, Gbem T, Elenschneider L, Jeck A, Day C, Hartley-Tassell L PLoS Negl Trop Dis. 2015; 9(10):e0004120.

PMID: 26474304 PMC: 4608562. DOI: 10.1371/journal.pntd.0004120.

HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth.

Acharya P, Lusvarghi S, Bewley C, Kwong P Expert Opin Ther Targets. 2015; 19(6):765-83.

PMID: 25724219 PMC: 4711772. DOI: 10.1517/14728222.2015.1010513.

References

Doores K, Bonomelli C, Harvey D, Vasiljevic S, Dwek R, Burton D . Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci U S A. 2010; 107(31):13800-5. PMC: 2922250. DOI: 10.1073/pnas.1006498107. View

Fujikawa K, Tsukamoto Y, Oki T, Lee Y . Spectroscopic studies on the interaction of pradimicin BMY-28864 with mannose derivatives. Glycobiology. 1998; 8(4):407-14. DOI: 10.1093/glycob/8.4.407. View

Saitoh K, Tsuno T, Kakushima M, Hatori M, FURUMAI T, Oki T . Pradimicin S, a new pradimicin analog. II. Isolation and structure elucidation. J Antibiot (Tokyo). 1993; 46(3):406-11. DOI: 10.7164/antibiotics.46.406. View

Saitoh K, Tenmyo O, Yamamoto S, FURUMAI T, Oki T . Pradimicin S, a new pradimicin analog. I. Taxonomy, fermentation and biological activities. J Antibiot (Tokyo). 1993; 46(4):580-8. DOI: 10.7164/antibiotics.46.580. View

Nakagawa Y, Doi T, Masuda Y, Takegoshi K, Igarashi Y, Ito Y . Mapping of the primary mannose binding site of pradimicin A. J Am Chem Soc. 2011; 133(43):17485-93. DOI: 10.1021/ja207816h. View

Oki T, Konishi M, Tomatsu K, Tomita K, Saitoh K, Tsunakawa M . Pradimicin, a novel class of potent antifungal antibiotics. J Antibiot (Tokyo). 1988; 41(11):1701-4. DOI: 10.7164/antibiotics.41.1701. View

McLellan J, Pancera M, Carrico C, Gorman J, Julien J, Khayat R . Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature. 2011; 480(7377):336-43. PMC: 3406929. DOI: 10.1038/nature10696. View

Nakagawa Y, Masuda Y, Yamada K, Doi T, Takegoshi K, Igarashi Y . Solid-state NMR spectroscopic analysis of the Ca2+-dependent mannose binding of pradimicin A. Angew Chem Int Ed Engl. 2011; 50(27):6084-8. DOI: 10.1002/anie.201007775. View

Go E, Chang Q, Liao H, Sutherland L, Alam S, Haynes B . Glycosylation site-specific analysis of clade C HIV-1 envelope proteins. J Proteome Res. 2009; 8(9):4231-42. PMC: 2756219. DOI: 10.1021/pr9002728. View

10.

Tanabe A, Nakashima H, Yoshida O, Yamamoto N, Tenmyo O, Oki T . Inhibitory effect of new antibiotic, pradimincin A on infectivity, cytopathic effect and replication of human immunodeficiency virus in vitro. J Antibiot (Tokyo). 1988; 41(11):1708-10. DOI: 10.7164/antibiotics.41.1708. View

11.

Mayer M, Meyer B . Characterization of Ligand Binding by Saturation Transfer Difference NMR Spectroscopy. Angew Chem Int Ed Engl. 2018; 38(12):1784-1788. DOI: 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q. View

12.

Li M, Gao F, Mascola J, Stamatatos L, Polonis V, Koutsoukos M . Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol. 2005; 79(16):10108-25. PMC: 1182643. DOI: 10.1128/JVI.79.16.10108-10125.2005. View

13.

Ueki T, Numata K, Sawada Y, Nakajima T, Fukagawa Y, Oki T . Studies on the mode of antifungal action of pradimicin antibiotics. I. Lectin-mimic binding of BMY-28864 to yeast mannan in the presence of calcium. J Antibiot (Tokyo). 1993; 46(1):149-61. DOI: 10.7164/antibiotics.46.149. View

14.

Balzarini J, Francois K, Van Laethem K, Hoorelbeke B, Renders M, Auwerx J . Pradimicin S, a highly soluble nonpeptidic small-size carbohydrate-binding antibiotic, is an anti-HIV drug lead for both microbicidal and systemic use. Antimicrob Agents Chemother. 2010; 54(4):1425-35. PMC: 2849379. DOI: 10.1128/AAC.01347-09. View

15.

Hansman G, Shahzad-Ul-Hussan S, McLellan J, Chuang G, Georgiev I, Shimoike T . Structural basis for norovirus inhibition and fucose mimicry by citrate. J Virol. 2011; 86(1):284-92. PMC: 3255897. DOI: 10.1128/JVI.05909-11. View

16.

Bertaux C, Daelemans D, Meertens L, Cormier E, Reinus J, Peumans W . Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions. Virology. 2007; 366(1):40-50. DOI: 10.1016/j.virol.2007.04.008. View